Top-line results from phase 3 focus trial of Kyrpolis®
AMGEN ANNOUNCES TOP-LINE RESULTS FROM Phase 3 FOCUS TRIAL of KYPROLIS® IN PATIENTS WITH RELAPSED AND ADVANCED REFRACTORY MULTIPLE MYELOMA THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. (Aug. 13, 2014) – Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The…